Literature DB >> 16528025

Characterization and immunological analysis of the rhesus cytomegalovirus homologue (Rh112) of the human cytomegalovirus UL83 lower matrix phosphoprotein (pp65).

Yujuan Yue1, Amitinder Kaur2, Shan Shan Zhou1, Peter A Barry3,4,1.   

Abstract

Rhesus cytomegalovirus (RhCMV) contains two open reading frames (Rh111 and Rh112) that encode proteins homologous to the phosphoprotein 65 (pp65) of the human cytomegalovirus (HCMV) UL83 gene. As HCMV pp65 elicits protective immune responses in infected humans and represents an important vaccination target, one RhCMV homologue of HCMV pp65, pp65-2 (Rh112), was characterized and analysed for its ability to induce host immune responses. Similar to its HCMV counterpart, RhCMV pp65-2 was expressed as a late gene, localized to the nucleus within pp65-2-expressing cells and was present within infectious virions. Longitudinal and cross-sectional studies of pp65-2 immunity in naturally infected rhesus macaques showed that humoral responses to pp65-2 were elicited early during infection, but were not always sustained over time. In contrast, pp65-2-specific T-cell responses, examined by gamma interferon ELISPOT, were broadly detectable in all of the animals studied during primary infection and persisted in the vast majority of RhCMV-seropositive monkeys. Moreover, there was considerable inter-animal variability in the pattern of the immune responses to pp65-2. Together, these results demonstrated that RhCMV pp65-2 exhibited biological and immunological homology to HCMV pp65. Thus, the rhesus macaque model of HCMV persistence and pathogenesis should be relevant for addressing pp65-based vaccine modalities.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16528025     DOI: 10.1099/vir.0.81516-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  20 in total

1.  Development of a novel, guinea pig-specific IFN-γ ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine.

Authors:  Peter A Gillis; Nelmary Hernandez-Alvarado; Josephine S Gnanandarajah; Felix Wussow; Don J Diamond; Mark R Schleiss
Journal:  Vaccine       Date:  2014-05-20       Impact factor: 3.641

2.  Neutralization of rhesus cytomegalovirus IL-10 reduces horizontal transmission and alters long-term immunity.

Authors:  Jesse D Deere; W L William Chang; Andradi Villalobos; Kimberli A Schmidt; Ashlesha Deshpande; Luis D Castillo; Joseph Fike; Mark R Walter; Peter A Barry; Dennis J Hartigan-O'Connor
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-12       Impact factor: 11.205

Review 3.  Animal Models of Congenital Cytomegalovirus Transmission: Implications for Vaccine Development.

Authors:  Hunter K Roark; Jennifer A Jenks; Sallie R Permar; Mark R Schleiss
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

4.  Rhesus and human cytomegalovirus glycoprotein L are required for infection and cell-to-cell spread of virus but cannot complement each other.

Authors:  J Jason Bowman; Juan C Lacayo; Peter Burbelo; Elizabeth R Fischer; Jeffrey I Cohen
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

5.  Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques.

Authors:  Kristina Abel; Joy Martinez; Yujuan Yue; Simon F Lacey; Zhongde Wang; Lisa Strelow; Anindya Dasgupta; Zhongqi Li; Kimberli A Schmidt; Kristie L Oxford; Basel Assaf; Jeffrey A Longmate; Don J Diamond; Peter A Barry
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

6.  Reevaluation of the coding potential and proteomic analysis of the BAC-derived rhesus cytomegalovirus strain 68-1.

Authors:  Daniel Malouli; Ernesto S Nakayasu; Kasinath Viswanathan; David G Camp; W L William Chang; Peter A Barry; Richard D Smith; Klaus Früh
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

7.  The susceptibility of primary cultured rhesus macaque kidney epithelial cells to rhesus cytomegalovirus strains.

Authors:  Yujuan Yue; Amitinder Kaur; Anders Lilja; Don J Diamond; Mark R Walter; Peter A Barry
Journal:  J Gen Virol       Date:  2016-03-14       Impact factor: 3.891

8.  A heterologous DNA prime/protein boost immunization strategy for rhesus cytomegalovirus.

Authors:  Kristina Abel; Lisa Strelow; Yujuan Yue; Meghan K Eberhardt; Kimberli A Schmidt; Peter A Barry
Journal:  Vaccine       Date:  2008-08-27       Impact factor: 3.641

9.  Functional genetic analysis of rhesus cytomegalovirus: Rh01 is an epithelial cell tropism factor.

Authors:  Anders E Lilja; W L William Chang; Peter A Barry; S Patricia Becerra; Thomas E Shenk
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

10.  Limited dissemination and shedding of the UL128 complex-intact, UL/b'-defective rhesus cytomegalovirus strain 180.92.

Authors:  Basel T Assaf; Keith G Mansfield; Lisa Strelow; Susan V Westmoreland; Peter A Barry; Amitinder Kaur
Journal:  J Virol       Date:  2014-06-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.